Sanofi-Aventis has announced the results of a head-to-head study of once-daily, 24-hour basal insulin Lantus compared to twice-daily insulin Detemir. The study was a head-to-head, randomised, non-inferiority controlled
Novartis has posted initial results from the two-year phase III FREEDOMS study, which shows that oral FTY720 (fingolimod) was superior to placebo in reducing both relapses and disability
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced results from a randomised, placebo-controlled phase 2 trial sponsored by Northwestern University. The study, which evaluated Nexavar (sorafenib) tablets in
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert to the healthcare community advising them of the recall of the human papillomavirus (HPV) vaccination
Caraco Pharmaceutical Laboratories has entered into a consent decree with the US Food and Drug Administration regarding the company’s drug manufacturing operations. The decree provides a series of
The National Rheumatoid Arthritis Society (NRAS) is urging the National Institute for Clinical Excellence (NICE) to reconsider its recommendation in the Appraisal Consultation Document issued on 1st October,
AlphaRx has entered into an exclusive collaboration and licensing agreement with Riso Pharma Tech for the development of ARX606T, an early stage product candidate intended for wound treatment.
Hospira has announced the acquisition of worldwide rights to a biogeneric version of filgrastim and an affiliated European manufacturing facility from PLIVA Hrvatska. Filgrastim is a granulocyte colony-stimulating
Germany-based Merck has submitted a new drug application (NDA) to the FDA for Cladribine tablets, an investigational oral formulation of cladribine, as a therapy for reducing relapses in
Ablynx under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth, has reached a second milestone. A milestone payment of $4m has been triggered by
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.